Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

News >

Biosimilars Poised to Have Global Impact on Oncology

Brandon Scalea
Published: Tuesday, Aug 28, 2018

Sunil Verma, MD
Sunil Verma, MD
As costs continue to trend upward in oncology, a comprehensive plan must be established so that patients with cancer can continue to receive systemic therapy, said Sunil Verma, MD.

While the implementation of biosimilars would likely assist in reducing cancer treatment costs, Verma added that there are other important factors to consider. For example, researchers need a better benchmark for what is said to be “clinically meaningful” in order to focus on the cost-effective treatment options with the greatest benefit.

“We need to set up structures to assess things like overall response and other important data so we can ultimately provide the best possible treatment,” said Verma, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre.

Several biosimilars have been approved by the FDA, including the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst) for use in patients with HER2-positive breast cancer, in addition to HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase III data from the HERITAGE trial presented at the 2018 ASCO Annual Meeting indicated clear equivalence for MYL-1401O compared with standard trastuzumab. MYL-1401O in combination with taxane-based chemotherapy for frontline treatment of patients with HER2-positive breast cancer mirrored the progression-free survival rate of patients treated in the same setting with trastuzumab.

In an interview with OncLive®, Verma shared insight on the benefits and unanswered questions that remain with biosimilars in oncology.

OncLive: What impact would the implementation of biosimilars have?

Verma: There are a couple aspects to look at when we talk about global impact. One would be the cost of care. The second would be the integration of these new agents. In terms of cost of care, introducing biosimilars would reduce the burden of cost that's becoming an issue all over the world. This is especially true for biologic agents in cancer. The numbers [for biosimilar costs] are quite durable between what we've seen in North America and what we see across to Europe. Depending on what kind of cost reductions we get, this would have a significant impact.

The secondary impact would be our ability to then shift these walls and integrate these new therapies so people can have access to them. We have to look at it in a way that allows any patient with cancer to have the option of a number of new, innovative treatments. If this comes to be, and we see an improvement in patient outcomes, that would be great for oncology. We're hoping this will be the case.

Why might there still be skepticism regarding biosimilars?

Mainly, the skepticism is that it remains to be seen what the cost reduction would look like. It is [unknown] how we are going to be able to collect real-world evidence to measure the integration of biosimilars. This has not been fully assessed yet. Also, there is skepticism because biosimilars would essentially replace therapies that have been providing significant clinical value to our patients. Any time you introduce a change, there's always this healthy doubt. Patients and oncologists want to be absolutely sure something works before they use it. Therefore, we need to make sure we're implementing new agents that are doing what they're labeled to do—and that is reducing cost and providing similar clinical benefit.

Do drug manufacturers pose a challenge in terms of implementing a more cost-driven solution?

It's hard to know. There will certainly be a competitive threat any time you want to introduce a new biosimilar. It is hard to say what this could mean for the drug companies, especially if a biosimilar could devalue one of their brands. In the clinical realm, we need to be supportive of methods that will lead to cost reduction. We need to have innovation in mind as the most important thing. Would biosimilars lead to greater innovation? That's something we still have to decide. One dogma might be that biosimilars would be stemming innovation just because they're driving down costs. I would argue that it would create greater innovation if we can divert some of those dollars to other newer therapies.

If the cost of treatment continues to rise, is the field of oncology sustainable without biosimilars?

It's a very provocative question. I would like to think that the field of oncology has a bright road ahead. The interest and investment that exists both from the industry, researchers, patients, and academia will lead to better therapy. The only way we can sustain and accelerate this is to address cost. Biosimilars would be one element, but it's not the only element. It's part of the approach.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x